SCHEMBL1135009

SCHEMBL1135009

CCNc1c(C=O)cnc2c1cnn2Cc1ccc(OC)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.48
ALDH1A1 P00352 3/20 0.48
MAPT P10636 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
HPGD P15428 2/20 0.47
ALOX15 P16050 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
HSD17B10 Q99714 1/20 0.47
PDE4B Q07343 1/20 0.44
PDE1A P54750 3/20 0.43
PDE1B Q01064 3/20 0.43
PDE1C Q14123 3/20 0.43
GAA P10253 1/20 0.43
ADORA1 P30542 3/20 0.43
NPBWR1 P48145 4/20 0.42
PDE5A O76074 1/20 0.41
MCHR1 Q99705 1/20 0.39
PKM P14618 1/20 0.38
PKLR P30613 1/20 0.38
ACVR1B P36896 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15555724 0.89 LMNA (0.50) LMNAALDH1A1MAPTSMN1; SMN2HPGD
SCHEMBL1135057 0.84 LMNA (0.52) LMNAALDH1A1MAPTSMN1; SMN2HPGD
SCHEMBL582731 0.82 PDE4B (0.47) LMNAALDH1A1MAPTSMN1; SMN2HPGD
SCHEMBL583784 0.82 ALDH1A1 (0.49) LMNAALDH1A1MAPTSMN1; SMN2HPGD
SCHEMBL583465 0.80 PDE4B (0.56) PDE4BPDE1APDE1BPDE1C
SCHEMBL5260430 0.76 MAPT (0.47) LMNAALDH1A1MAPTSMN1; SMN2HPGD
SCHEMBL1311733 0.74 NPBWR1 (0.55) PDE1APDE1BPDE1CNPBWR1MCHR1
SCHEMBL583574 0.72 PDE5A (0.61) LMNAALDH1A1MAPTSMN1; SMN2HPGD
SCHEMBL5262030 0.72 ALDH1A1 (0.43) LMNAALDH1A1MAPTSMN1; SMN2HPGD
SCHEMBL21796715 0.71 NPBWR1 (0.51) LMNAALOX15PDE1APDE1BPDE1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2027123-B1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2011-02-23 EP disclosed
EP-2027123-B1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2011-02-23 EP disclosed
US-7846923-B2 Compounds and compositions as protein kinase inhbitors IRM LLC (BM) 2010-12-07 US disclosed
US-7846923-B2 Compounds and compositions as protein kinase inhbitors IRM LLC (BM) 2010-12-07 US disclosed
US-20100048552-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS IRM LLC (BM) 2010-02-25 US disclosed
US-20100048552-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS IRM LLC (BM) 2010-02-25 US disclosed
EP-2027123-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-02-25 EP disclosed
WO-2007134259-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2007-11-22 WO disclosed
WO-2007134259-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2007-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048552-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS BMX, FYN, FRK LMNA 4080/4885ALDH1A1 4202/4885MAPT 2536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.